Liberty Global Ltd Class C vs Twist Bioscience Corp — how do they compare? Liberty Global Ltd Class C trades at $8.5 (market cap $3.06B), while Twist Bioscience Corp trades at $160.35 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 3.3× Liberty Global Ltd Class C's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Global Ltd Class C for 21 Days and Twist Bioscience Corp for 27 Days on average.
| LBTYK | TWST | |
|---|---|---|
Market Cap | $3.06B | $10.08B |
Volume | 2,508,956 | 4,229,037 |
Sector | Media | Health |
52-Week High | $12.67 | $205.00 |
52-Week Low | $8.75 | $25.45 |
Typical Hold Time | 21 Days | 27 Days |
Enterprise Value | $9.72B | $10.01B |
Signals from Pluang's Aura AI — not financial advice
Liberty Global (LBTYK) trades at $8.41, down 5.72% on the day and near 52-week lows. The stock shows bearish technical signals with negative moving averages and oscillators, though RSI indicates oversold conditions. Fundamentally, the company reported a net loss of $7.14B in 2025 despite $4.88B revenue, but cash flow remains positive at $264.8M. Recent developments include the VodafoneZiggo acquisition and preparations for Ziggo Group's 2027 listing.
The outlook remains challenging with persistent losses and bearish technicals, but analyst consensus is bullish with a $12.67 price target. Key opportunities include Ziggo Group's planned spin-off and AI partnerships, while risks involve execution on profitability and competitive pressures in telecom markets.
Twist Bioscience (TWST) trades at $159.78, up 2.65% today, showing strong momentum despite mixed technical signals. The company continues to demonstrate robust revenue growth, with 2025 revenue reaching $377 million, though profitability remains elusive with a -31.66% net income margin. Recent positive developments include a strategic partnership with Eli Lilly's TuneLab AI platform announced September 16, 2026, driving investor optimism about the company's AI-driven drug discovery capabilities.
While analyst consensus remains bullish with 73% buy ratings, the stock faces significant fundamental challenges including persistent cash burn and negative earnings. The current price exceeds the $145.20 consensus target, suggesting limited near-term upside. Key risks include execution challenges in achieving profitability and dependence on AI partnerships for growth catalysts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →